Navigation Links
Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
Date:9/24/2008

Study to Assess the Safety and Efficacy of ORMD 0801, Oral Insulin Capsule,

on Type 1 Diabetics

JERUSALEM, Israel, September 24 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that it has commenced Phase 2A studies of ORMD 0801, its oral insulin capsule, on Type 1 diabetics at the Hadassah University Medical Center in Jerusalem, Israel.

Oramed's Phase 2A trial is focused on assessing the safety and efficacy of its oral insulin capsule on nine Type 1 diabetes patients.

The start of this clinical trial on Type 1 Diabetic patients follows completion by the company of similar trials on Type 2 diabetic patients, which demonstrated that ORMD 0801 had a good safety profile and was effective in lowering blood glucose levels without any serious adverse events.

"The commencement of trials of our oral insulin capsule on Type 1 diabetics signals another major step forward for our company in the treatment of diabetes," said Nadav Kidron, Oramed CEO. "The successful results from our trials on Type 2 diabetics were very encouraging and we hope to achieve similar results from our Type 1 trials as well."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oram
'/>"/>

SOURCE Oramed Pharmaceticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
2. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
3. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
4. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
5. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
6. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
7. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
8. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
9. Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
10. Vanda Pharmaceuticals Provides Update on Iloperidone
11. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 The Pennsylvania State Police will ... 27, as part of National Prescription Drug Take-Back Day. ... Take-Back Day is a national initiative, conducted ... aimed at encouraging the public to dispose of expired, ... abuse and theft. From 10 a.m. to ...
(Date:9/23/2014)... 23, 2014 Rising health ... and increasing number of foreign and domestic players in ... India   The ... most high growth potential markets worldwide due to multiple ... among the youth, changing food consumption patterns, increasing diabetic ...
(Date:9/23/2014)... Iowa , Sept. 23, 2014  KemPharm, ... the discovery and development of proprietary new molecular ... a No Objection Letter (NOL) from Health Canada ... for its lead product candidate KP201 ... prodrug in development for acute moderate to moderately ...
Breaking Medicine Technology:India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... Calif., Aug. 2, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the following investor ... Conference Location: Intercontinental Hotel, Boston, MA Presentation ... Wedbush Life Sciences ...
... Mich., Aug. 2, 2011 Perrigo Company (Nasdaq: PRGO;TASE) today ... quarter fiscal 2011 on Tuesday, August 16 , 2011 at ... call at 10:00 a.m. (ET) hosted by Joseph C. Papa, ... call will be available live via webcast to interested parties ...
Cached Medicine Technology:
(Date:9/23/2014)... PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN THE ... The National Institutes of Health is convening a Pathways ... on the long-term effectiveness and potential risks of opioids ... nation,s top experts in the field of pain control ... key NIH scientists who focus on pain related research. ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows all about ... can be treated. , A medically retired Army veteran, ... platoon sustained multiple attacks resulting in five casualties. After ... PTSD and honorably discharged from the Army. , “I ... myself from my friends and family,” recalled O’Farrell, who ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Dr. Connie Casad ... medical practices to new office space at 12200 Park Central ... at the office will be Park Cities Aesthetics, Optimal Health ... , In announcing her move, Dr. Casad said, “The patients’ ... treatment they select, we want them to always feel like ...
(Date:9/23/2014)... used to diagnose lung cancer may not be as reliable ... a new analysis says. One noninvasive way of ... as functional imaging. For lung cancer, a specific type of ... authors. Cancerous tumors generally look different on FDG-PET images ... have cancer, according to background information in the study. But, ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Avid collector Andrew ... 1967 The Doors Eagle Auditorium Seattle concert posters. The Doors ... “Break On Through” that year. The Seattle Eagles Auditorium concert ... “The Doors would return to Eagles Auditorium in November the ... is not known and comes in three colors. The poster ...
Breaking Medicine News(10 mins):Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Dr. Connie Casad Moving to New Office Location 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2
... in the spread of lung cancer as well as a likely ... study was published today (Monday, March 14) in the Journal ... The University of Texas MD Anderson Cancer Center found a way ... that shifts primary tumor cells into a more deadly type of ...
... Harbor, N.Y In a research study appearing in the ... Cold Spring Harbor Laboratory (CSHL) and four other institutions have ... which currently has limited treatment options and one of the ... experiments reveal that up to 15% of liver tumors are ...
... March 14, 2011The first human studies of an oral drug ... promising near 50% reduction in HIV incidence, but a number ... can be implemented on a large scale, according to an ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( www.liebertpub.com ...
... Reporter , MONDAY, March 14 (HealthDay News) -- An ... earthquake-ravaged Japan,s Fukushima Dai-ichi nuclear complex, but officials insisted ... to news reports. Authorities had been scrambling ... earthquake and tsunami knocked out water systems and backup ...
... major study of the wellbeing and inclusion of former ... by Queen,s University today (Monday 14 March). ... in Northern Ireland and the border region of Ireland ... of loyalist and republican former prisoners (aged 50 and ...
... Researchers at Georgia Health Sciences University are studying ... protective metabolite could halt the progression of diabetic nephropathy, ... four year, $308,000 grant from the American Heart Association, ... the College of Dental Medicine and Pharmacology and Toxicology ...
Cached Medicine News:Health News:Study puts notch on the jagged edge of lung cancer metastasis 2Health News:Study puts notch on the jagged edge of lung cancer metastasis 3Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 2Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 3Health News:Early success of anti-HIV preventive oral drug regimen is promising, but questions remain 2Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 2Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 3Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 4Health News:Report into well-being and inclusion of former politically motivated prisoners 2Health News:Report into well-being and inclusion of former politically motivated prisoners 3
... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: